Archives
-
SU 5402: Mechanism, Scope, and Evidence Limits
2026-10-16
APExBIO identifies SU 5402, also called SU-5402, as a multi-target receptor tyrosine kinase inhibitor associated with VEGFR2, FGFR1, PDGFRβ, and comparatively weak EGFR inhibition. The available information supports a catalog-level mechanistic model involving receptor phosphorylation, ERK1/2 and STAT3 signaling, and reported cell-cycle or apoptotic phenotypes, but no identity-matched primary paper is available here to establish assay context, reproducibility, effect sizes, or translational relevance.
-
What the EGFP sgRNA Product Record Establishes
2026-10-16
The APExBIO product record identifies SKU R2997 as three sgRNAs described as targeting EGFP in HeLa cells, with a listed amount of 3 µmol per guide. It does not provide sequences, nuclease context, validation data, or study results, so the record supports a limited identity and conceptual mechanism overview—not claims about editing efficiency, fluorescence changes, specificity, or cellular performance.
-
Evacetrapib: What the Product Record Establishes
2026-10-15
The APExBIO listing identifies Evacetrapib (LY2484595), SKU A4377, but supplies no product description, mechanism, measurement principle, or study outcomes. Accordingly, the evidence supports a documented identity overview only, not claims about biological activity, performance, or clinical relevance.
-
NVP-BGJ398 Phosphate: FGFR Scope and Evidence
2026-10-15
NVP-BGJ398 phosphate, also described here as BGJ-398 phosphate, is presented by APExBIO as a selective pan-FGFR1–3 inhibitor with lower potency against FGFR4. The available documentation supports a supplier-attributed mechanism and several proposed research contexts, but no identity-matched research paper is available to independently verify the reported activities, model outcomes, or clinical-development status.
-
NVP-BGJ398 Phosphate: Evidence and Scope
2026-10-14
NVP-BGJ398 phosphate, also called BGJ-398 phosphate, is described by APExBIO as a selective FGFR1–3 inhibitor that acts by suppressing receptor autophosphorylation and downstream signaling such as ERK1/2. The available evidence here is catalog-level rather than identity-matched primary research, so reported potency, cancer-model activity, and translational relevance should be treated as documented claims with important limits.
-
A Bivalent mRNA Vaccine for H5/H7 Avian Influenza
2026-10-14
Wei et al. report preclinical evidence that a bivalent mRNA–lipid nanoparticle vaccine targeting H5N1 and H7N9 hemagglutinin induced broad immune responses and protected specific-pathogen-free chickens from several homologous and heterologous virus challenges. The findings are promising but remain bounded by the controlled SPF-chicken model and the study’s limited evidence on durability, field effectiveness, safety, and population-level transmission.
-
Recombinant Human FGF-19: Evidence and Scope
2026-10-13
The APExBIO product page identifies a tag-free, lyophilized recombinant human FGF-19 protein expressed in E. coli and presents vendor-reported binding, cell-assay, purity, and endotoxin specifications. No matched peer-reviewed paper was provided, so the evidence supports product identity and stated conceptual research scope—not independent confirmation of mechanism, therapeutic activity, or performance across biological systems.
-
Lovastatin: Evidence, Mechanism, and Boundaries
2026-10-13
Lovastatin is an HMG-CoA reductase inhibitor with broadly reported effects across cholesterol, isoprenoid, proliferation, and inflammatory-cell models. Those findings should not be conflated with the supplied Arabidopsis study, which identifies KNUCKLES as a regulator of auxin distribution and cytokinin activity during floral meristem termination but does not test Lovastatin or the mevalonate pathway.
-
Corynoline, Apoptosis, and Evidence Boundaries
2026-10-12
A 2025 study reports that corynoline suppressed osteosarcoma models through effects associated with G2/M arrest, mitochondrial apoptosis, and Src/JNK signaling. The findings are mechanistically suggestive but remain preclinical; the supplied summary does not establish a direct molecular target, clinical benefit, or long-term safety.
-
WIP1, p38 MAPK, and Pyroptosis in Septic AKI
2026-10-12
Wang et al. investigate whether WIP1/PPM1D restrains p38 MAPK-associated pyroptosis in sepsis-associated acute kidney injury. Their integrated evidence from single-cell transcriptomics, human acute tubular injury samples, mouse injury models, and HK2 cells is consistent with WIP1 acting as a protective regulator, although pharmacological and model-specific limitations prevent direct clinical conclusions. Recombinant Human FGF-19 is discussed separately because no connection to FGF-19 is documented in the cited study.
-
FLCN mRNA Rescue in Birt-Hogg-Dubé: What It Shows
2026-10-11
A 2026 study identified two FLCN variants in Chinese Birt-Hogg-Dubé families and found that exogenous FLCN mRNA restored protein expression and normalized an mTORC1-related readout in cultured cells. The results support pathogenicity assessment and an early proof of concept, but they do not establish clinical efficacy or a therapeutic route.
-
Tiamulin (Thiamutilin): Metabolism, Evidence & Limits
2026-10-10
Tiamulin (Thiamutilin) is examined through a metabolite-first lens that connects ribosomal pharmacology with species-specific residue science. This evidence-focused review clarifies what is established, what remains exploratory, and why parent-drug measurements alone can mislead veterinary interpretation.
-
Exendin-4: From GLP-1 Biology to Translation
2026-10-09
Exendin-4 is more than a GLP-1 receptor agonist used in beta cell experiments: it is a mechanistic reference point for connecting cAMP signaling, metabolic phenotypes, and emerging manufacturing strategies. This evidence-led perspective examines what recent yeast-expression research establishes, where translational uncertainty remains, and how researchers can frame Exendin-4 and Exenatide within a credible type 2 diabetes research strategy.
-
Vitamin D/VDR and Endometrial Decidualization
2026-10-09
This study identifies the vitamin D/vitamin D receptor (VDR) axis as a positive regulator of human endometrial stromal cell decidualization. Its findings connect VDR activity with CYP19-mediated estrogen signaling, while the in vitro design defines an important mechanistic hypothesis rather than establishing clinical efficacy.
-
Plk1 Regulation of p31comet in Checkpoint Exit
2026-10-08
The reference study identifies Polo-like kinase 1 (Plk1) as a negative regulator of p31comet-mediated mitotic checkpoint complex disassembly. Its biochemical and mutational evidence supports a model in which phosphorylation of p31comet at S102 restrains TRIP13-assisted checkpoint silencing and helps prevent premature mitotic exit.